Rouba Kozak
Affiliations: | Pfizer, Inc., San Diego, CA, United States |
Area:
NeuropsychopharmacologyWebsite:
http://www.pfizer.com/pfizer/main.jspGoogle:
"Rouba Kozak"Cross-listing: Neurotree
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Moore TL, Young DA, Killiany RJ, et al. (2021) The Effects of a Novel Non-catechol Dopamine Partial Agonist on Working Memory in the Aged Rhesus Monkey. Frontiers in Aging Neuroscience. 13: 757850 |
| Kozak R, Kiss T, Dlugolenski K, et al. (2020) Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation. Frontiers in Pharmacology. 11: 1005 |
| Balice-Gordon R, Honey GD, Chatham C, et al. (2020) A Neurofunctional Domains Approach to Evaluate D1/D5 Dopamine Receptor Partial Agonism on Cognition and Motivation in Healthy Volunteers With Low Working Memory Capacity. The International Journal of Neuropsychopharmacology |
| Young D, Popiolek M, Trapa P, et al. (2020) D1 agonist improved movement of parkinsonian nonhuman primates with limited dyskinesia side effects. Acs Chemical Neuroscience |
| Soutschek A, Kozak R, de Martinis N, et al. (2020) Activation of D1 receptors affects human reactivity and flexibility to valued cues. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology |
| Arce E, Balice-Gordon R, Duvvuri S, et al. (2019) A novel approach to evaluate the pharmacodynamics of a selective dopamine D1/D5 receptor partial agonist (PF-06412562) in patients with stable schizophrenia. Journal of Psychopharmacology (Oxford, England). 269881119855302 |
| Wang M, Datta D, Enwright J, et al. (2019) A novel dopamine D1 receptor agonist excites delay-dependent working memory-related neuronal firing in primate dorsolateral prefrontal cortex. Neuropharmacology |
| Davoren JE, Nason DM, Coe J, et al. (2018) Discovery and Lead Optimization of Atropisomer D1 Agonists with Reduced Desensitization. Journal of Medicinal Chemistry |
| Gilmour G, Porcelli S, Bertaina-Anglade V, et al. (2018) Relating constructs of attention and working memory to social withdrawal in Alzheimer's disease and schizophrenia: issues regarding paradigm selection. Neuroscience and Biobehavioral Reviews |
| Popiolek M, Mandelblat-Cerf Y, Young D, et al. (2018) In vivo modulation of hippocampal excitability by M4 muscarinic acetylcholine receptor activator: implications for treatment of Alzheimer's disease and schizophrenic patients. Acs Chemical Neuroscience |